JGC
PPH icon

J. Goldman & Co’s VanEck Pharmaceutical ETF PPH Stock Holding History

J. Goldman & Co’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-67,015
Closed -$6.06M – 695
2025
Q3 		$6.06M Buy
+67,015
New +$5.87M 0.15% 182

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

J. Goldman & Co's PPH Position: Q4 2025 in Review

J. Goldman & Co sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2025, closing a stake of 67,015 shares — an estimated $6.06M sold.

J. Goldman & Co first reported a position in PPH in Q3 2025 and held it in 1 quarter. The position peaked at $6.06M in Q3 2025. 146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

  • J. Goldman & Co reported no remaining VanEck Pharmaceutical ETF position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 67,015 VanEck Pharmaceutical ETF shares in Q4 2025, an estimated $6.06M.
  • J. Goldman & Co first reported a position in VanEck Pharmaceutical ETF in Q3 2025 and held it in 1 quarter.
  • J. Goldman & Co's VanEck Pharmaceutical ETF position peaked at $6.06M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.